Espero Pharmaceuticals to Present at 9th Annual Biotech Showcase
JACKSONVILLE, Fla. (December 20, 2016) – Espero Pharmaceuticals, Inc., a commercial-stage cardiovascular pharmaceutical company, announced today that the company has been invited to present at the 9th Annual Biotech Showcase in San Francisco from January 9-11, 2017.
Quang Pham, Chief Executive Officer, and Jeff Cole, President and Chief Financial Officer, will provide an update on the company’s operations, sales, and business development activities on January 11 at 1:45 p.m. PT. The company’s executives will also attend the activities surrounding the concurrent JP Morgan Healthcare Conference and meet with investors and potential pharmaceutical company partners.
Espero recently announced the commercial availability of GONITRO™, a FDA-approved short-acting nitrate in a patented, stabilized crystal granule form available in single dose packets for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. GONITRO™ is the first product approved to treat acute angina in the U.S. in nearly 20 years.
About the Annual Biotech Showcase The Annual BioTech Showcase is one of the industry’s largest annual healthcare investor and partnering conferences and regarded as biotech’s most impactful week of the year. With more than 3,000 attendees and 1,600 company presentations, the Showcase is San Francisco’s exclusive investor and networking event. More information can be found here.
About Espero Pharmaceuticals
Espero Pharmaceuticals, Inc., www.esperopharma.com, is a commercial-stage cardiovascular pharmaceutical company engaged in maximizing the commercial value of proven treatments that improve the quality of life for patients. Espero is focused on compounds with proven safety and efficacy administered via novel delivery solutions in the cardiovascular and other specialty therapeutic categories. Through Jacksonville Pharmaceuticals, its wholly owned subsidiary, the company markets and distributes selected generic pharmaceutical products including the authorized generic version of Nitrolingual® Pumpspray (nitroglycerin lingual spray).